The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform

Nirmala Gonsalves - One of the best experts on this subject based on the ideXlab platform.

  • Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
    The New England journal of medicine, 2020
    Co-Authors: Evan S. Dellon, Robert M Genta, Kathryn A. Peterson, Joseph A. Murray, Gary W. Falk, Nirmala Gonsalves, Mirna Chehade, John Leung, Paneez Khoury, Amy D. Klion
    Abstract:

    Abstract Background Eosinophilic Gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, and a lack of adequate treatments. ...

  • anti siglec 8 antibody for Eosinophilic Gastritis and duodenitis
    The New England Journal of Medicine, 2020
    Co-Authors: Evan S. Dellon, Robert M Genta, Kathryn A. Peterson, Joseph A. Murray, Gary W. Falk, Nirmala Gonsalves, Mirna Chehade, John Leung, Paneez Khoury, Amy D. Klion
    Abstract:

    Abstract Background Eosinophilic Gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, and a lack of adequate treatments. ...

  • Eosinophilic Gastrointestinal Disorders
    Clinical reviews in allergy & immunology, 2019
    Co-Authors: Nirmala Gonsalves
    Abstract:

    Eosinophilic gastrointestinal disorders (EGID) are a group of disorders characterized by pathologic Eosinophilic infiltration of the esophagus, stomach, small intestine, or colon leading to organ dysfunction and clinical symptoms (J Pediatr Gastroenterol Nutr; Spergel et al., 52: 300–306, 2011). These disorders include Eosinophilic esophagitis (EoE), Eosinophilic Gastritis (EG), Eosinophilic gastroenteritis (EGE), Eosinophilic enteritis (EE), and Eosinophilic colitis (EC). Symptoms are dependent not only on the location (organ) as well as extent (layer invasion of the bowel wall). Common symptoms of EoE include dysphagia and food impaction in adults and heartburn, abdominal pain, and vomiting in children. Common symptoms of the other EGIDs include abdominal pain, nausea, vomiting, early satiety, diarrhea, and weight loss. These disorders are considered immune-mediated chronic inflammatory disorders with strong links to food allergen triggers. Treatment strategies focus on either medical or dietary therapy. These options include not only controlling symptoms and bowel inflammation but also on identifying potential food triggers. This chapter will focus on the clinical presentation, pathophysiology, and treatment of these increasingly recognized disorders.

  • Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment
    Digestive Diseases and Sciences, 2018
    Co-Authors: Alyse Bedell, Tiffany Taft, Meredith R. Craven, Livia Guadagnoli, Ikuo Hirano, Nirmala Gonsalves
    Abstract:

    Background Eosinophilic Gastritis (EG) and Eosinophilic gastroenteritis (EGE) are chronic immune-mediated conditions of the digestive tract, which affect the stomach only, or the stomach and small intestines, respectively. Though these disorders are uncommon, they are being increasingly recognized and diagnosed. While health-related quality of life (HRQOL) has been evaluated in other Eosinophilic gastrointestinal diseases, this study is the first to describe HRQOL impacts unique to EG/EGE. Aims This study aims to qualitatively describe experiences of adults diagnosed with EG and EGE. We aim to identify impacts on HRQOL in this population in order to inform clinical care and assessment. Methods Seven patients diagnosed with EG or EGE participated in semi-structured interviews assessing common domains of HRQOL. Results Four distinct themes emerged from qualitative analyses, which represent impacts to HRQOL: the psychological impact of the diagnosis, impact on social relationships, financial impact, and impact on the body. These generally improved over time and with effective treatment. Conclusions This study demonstrated that patients with EG/EGE experience impacts to HRQOL, some of which differ from HRQOL of other Eosinophilic gastrointestinal diseases. These results support the development of a disease-specific measure, or adaptation of an existing measure, to assess HRQOL in EG/EGE.

  • Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment
    Digestive diseases and sciences, 2018
    Co-Authors: Alyse Bedell, Livia Guadagnoli, Ikuo Hirano, Tiffany Noel Taft, Meredith Craven, Nirmala Gonsalves
    Abstract:

    Eosinophilic Gastritis (EG) and Eosinophilic gastroenteritis (EGE) are chronic immune-mediated conditions of the digestive tract, which affect the stomach only, or the stomach and small intestines, respectively. Though these disorders are uncommon, they are being increasingly recognized and diagnosed. While health-related quality of life (HRQOL) has been evaluated in other Eosinophilic gastrointestinal diseases, this study is the first to describe HRQOL impacts unique to EG/EGE. This study aims to qualitatively describe experiences of adults diagnosed with EG and EGE. We aim to identify impacts on HRQOL in this population in order to inform clinical care and assessment. Seven patients diagnosed with EG or EGE participated in semi-structured interviews assessing common domains of HRQOL. Four distinct themes emerged from qualitative analyses, which represent impacts to HRQOL: the psychological impact of the diagnosis, impact on social relationships, financial impact, and impact on the body. These generally improved over time and with effective treatment. This study demonstrated that patients with EG/EGE experience impacts to HRQOL, some of which differ from HRQOL of other Eosinophilic gastrointestinal diseases. These results support the development of a disease-specific measure, or adaptation of an existing measure, to assess HRQOL in EG/EGE.

Evan S. Dellon - One of the best experts on this subject based on the ideXlab platform.

Gary W. Falk - One of the best experts on this subject based on the ideXlab platform.

  • Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
    The New England journal of medicine, 2020
    Co-Authors: Evan S. Dellon, Robert M Genta, Kathryn A. Peterson, Joseph A. Murray, Gary W. Falk, Nirmala Gonsalves, Mirna Chehade, John Leung, Paneez Khoury, Amy D. Klion
    Abstract:

    Abstract Background Eosinophilic Gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, and a lack of adequate treatments. ...

  • anti siglec 8 antibody for Eosinophilic Gastritis and duodenitis
    The New England Journal of Medicine, 2020
    Co-Authors: Evan S. Dellon, Robert M Genta, Kathryn A. Peterson, Joseph A. Murray, Gary W. Falk, Nirmala Gonsalves, Mirna Chehade, John Leung, Paneez Khoury, Amy D. Klion
    Abstract:

    Abstract Background Eosinophilic Gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, and a lack of adequate treatments. ...

  • increasing rates of diagnosis substantial co occurrence and variable treatment patterns of Eosinophilic Gastritis gastroenteritis and colitis based on 10 year data across a multicenter consortium
    The American Journal of Gastroenterology, 2019
    Co-Authors: Robert D Pesek, Gary W. Falk, Amanda B. Muir, Craig C Reed, Patricia C Fulkerson, Calies Menardkatcher, Jonathan Kuhl, Ellen K Martin, Adam Z Magier, Faria N Ahmed
    Abstract:

    OBJECTIVES:The literature related to Eosinophilic Gastritis (EG), gastroenteritis (EGE), and colitis (EC) is limited. We aimed to characterize rates of diagnosis, clinical features, and initial treatments for patients with EG, EGE, and EC.METHODS:In this retrospective study, data were collected from

  • Increasing Rates of Diagnosis, Substantial Co-occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis and Colitis Based on 10 Year Data Across a Multi-Center Consortium
    2018
    Co-Authors: Robert D Pesek, Gary W. Falk, Amanda B. Muir, Craig C Reed, Patricia C Fulkerson, Jonathan Kuhl, Adam Z Magier, Faria N Ahmed, Calies Menard-katcher, Maureen Demarshall
    Abstract:

    Objective: The literature related to Eosinophilic Gastritis (EG), gastroenteritis (EGE) and colitis (EC) is limited. We aimed to characterize rates of diagnosis, clinical features, and initial treatments of patients with EG, EGE, and EC. Methods: In this retrospective study, data were collected from six centers in the Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR) from 2005-2016. We analyzed demographics, time trends in diagnosis, medical history, presenting symptoms, disease overlap, and initial treatment patterns. Results: Of 373 subjects (317 children and 56 adults), 38% had EG, 33% EGE, and 29% EC. Rates of diagnosis for all diseases increased over time. There was no male predominance, and the majority of subjects had atopy. Presenting symptoms were similar between diseases with nausea/vomiting and abdominal pain the most common. 154 subjects (41%) had Eosinophilic inflammation outside of their primary disease location with the esophagus the most common second GI segment involved. Multi-site inflammation was more common in children than adults (68% vs 37%; p

  • increasing rates of diagnosis substantial co occurrence and variable treatment patterns of Eosinophilic Gastritis gastroenteritis and colitis based on 10 year data across a multi center consortium
    bioRxiv, 2018
    Co-Authors: Robert D Pesek, Gary W. Falk, Amanda B. Muir, Craig C Reed, Patricia C Fulkerson, Calies Menardkatcher, Jonathan Kuhl, Adam Z Magier, Faria N Ahmed, Maureen Demarshall
    Abstract:

    Objective: The literature related to Eosinophilic Gastritis (EG), gastroenteritis (EGE) and colitis (EC) is limited. We aimed to characterize rates of diagnosis, clinical features, and initial treatments of patients with EG, EGE, and EC. Methods: In this retrospective study, data were collected from six centers in the Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR) from 2005-2016. We analyzed demographics, time trends in diagnosis, medical history, presenting symptoms, disease overlap, and initial treatment patterns. Results: Of 373 subjects (317 children and 56 adults), 38% had EG, 33% EGE, and 29% EC. Rates of diagnosis for all diseases increased over time. There was no male predominance, and the majority of subjects had atopy. Presenting symptoms were similar between diseases with nausea/vomiting and abdominal pain the most common. 154 subjects (41%) had Eosinophilic inflammation outside of their primary disease location with the esophagus the most common second GI segment involved. Multi-site inflammation was more common in children than adults (68% vs 37%; p<0.001). Initial treatment patterns highly varied between centers. Food elimination diets were used in over half of subjects and combined treatment with diet and medication was common. Conclusions: In this cohort, EG, EGE, and EC were diagnosed more frequently over time and inflammation of GI segments outside the primary disease site, lack of male predominance, and co-occurrence of atopy was common. Symptoms were similar between diseases and initial treatment strategies were highly variable. Future investigation should assess the cause of increased EGID prevalence and prospectively assess outcomes to establish treatment algorithms.

Mirna Chehade - One of the best experts on this subject based on the ideXlab platform.

  • diagnostic delay in patients with Eosinophilic Gastritis and or duodenitis a population based study
    The Journal of Allergy and Clinical Immunology: In Practice, 2021
    Co-Authors: Mirna Chehade, Dan Atkins, Amol P Kamboj, Lauren Gehman
    Abstract:

    Background Eosinophilic Gastritis and/or Eosinophilic duodenitis (EG/EoD) is characterized by persistent symptoms and elevated eosinophils in the gastrointestinal tract. Limited disease awareness and lack of diagnostic guidelines suggest that patients may remain undiagnosed or endure diagnostic delay. Objective To characterize the path to diagnosis for patients with EG/EoD in a representative population. Methods In this observational cohort study, 4108 eligible patients diagnosed with EG/EoD between 2008 and 2018 were identified in an administrative claims database in the United States. Patient medical claim history was analyzed to describe events related to diagnosis. Results Mean year from symptom presentation to diagnosis of EG/EoD was 3.6; factors contributing to diagnostic delay included delayed gastroenterologist referral, delayed esophagogastroduodenoscopy (EGD), and lack of biopsy collection and/or histopathologic evaluation. Missed diagnosis on index EGD occurred in 38.2% of patients, resulting in a mean increase of 1.6 years in time to diagnosis versus patients diagnosed on index EGD. Patients presented with nonspecific symptoms and 44.3% were diagnosed with another gastrointestinal condition before EG/EoD diagnosis. Independent predictors of >2-year diagnostic delay included adult age; prior diagnosis of irritable bowel syndrome, functional dyspepsia, or gastric/peptic ulcer; use of other procedures such as colonoscopy; presence of edema; and history of certain allergic diseases. Conclusions This study found that patients with EG/EoD experienced an average of 3.6 years between initial symptom presentation and diagnosis and revealed several factors contributing to diagnostic delay. We hope that these findings, together with heightened awareness and standardization of diagnostic guidelines, will improve the diagnostic journey of patients with EG/EoD.

  • Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study
    The journal of allergy and clinical immunology. In practice, 2021
    Co-Authors: Mirna Chehade, Dan Atkins, Amol P Kamboj, Lauren Gehman
    Abstract:

    Background Eosinophilic Gastritis and/or Eosinophilic duodenitis (EG/EoD) is characterized by persistent symptoms and elevated eosinophils in the gastrointestinal tract. Limited disease awareness and lack of diagnostic guidelines suggest that patients may remain undiagnosed or endure diagnostic delay. Objective To characterize the path to diagnosis for patients with EG/EoD in a representative population. Methods In this observational cohort study, 4108 eligible patients diagnosed with EG/EoD between 2008 and 2018 were identified in an administrative claims database in the United States. Patient medical claim history was analyzed to describe events related to diagnosis. Results Mean year from symptom presentation to diagnosis of EG/EoD was 3.6; factors contributing to diagnostic delay included delayed gastroenterologist referral, delayed esophagogastroduodenoscopy (EGD), and lack of biopsy collection and/or histopathologic evaluation. Missed diagnosis on index EGD occurred in 38.2% of patients, resulting in a mean increase of 1.6 years in time to diagnosis versus patients diagnosed on index EGD. Patients presented with nonspecific symptoms and 44.3% were diagnosed with another gastrointestinal condition before EG/EoD diagnosis. Independent predictors of >2-year diagnostic delay included adult age; prior diagnosis of irritable bowel syndrome, functional dyspepsia, or gastric/peptic ulcer; use of other procedures such as colonoscopy; presence of edema; and history of certain allergic diseases. Conclusions This study found that patients with EG/EoD experienced an average of 3.6 years between initial symptom presentation and diagnosis and revealed several factors contributing to diagnostic delay. We hope that these findings, together with heightened awareness and standardization of diagnostic guidelines, will improve the diagnostic journey of patients with EG/EoD.

  • Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
    The New England journal of medicine, 2020
    Co-Authors: Evan S. Dellon, Robert M Genta, Kathryn A. Peterson, Joseph A. Murray, Gary W. Falk, Nirmala Gonsalves, Mirna Chehade, John Leung, Paneez Khoury, Amy D. Klion
    Abstract:

    Abstract Background Eosinophilic Gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, and a lack of adequate treatments. ...

  • anti siglec 8 antibody for Eosinophilic Gastritis and duodenitis
    The New England Journal of Medicine, 2020
    Co-Authors: Evan S. Dellon, Robert M Genta, Kathryn A. Peterson, Joseph A. Murray, Gary W. Falk, Nirmala Gonsalves, Mirna Chehade, John Leung, Paneez Khoury, Amy D. Klion
    Abstract:

    Abstract Background Eosinophilic Gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, and a lack of adequate treatments. ...

  • Eosinophilic Gastritis in children clinicopathological correlation disease course and response to therapy
    The American Journal of Gastroenterology, 2014
    Co-Authors: Raffaella A Morotti, Oksana Yershov, Mirna Chehade
    Abstract:

    Eosinophilic Gastritis in Children: Clinicopathological Correlation, Disease Course, and Response to Therapy

Amy D. Klion - One of the best experts on this subject based on the ideXlab platform.